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Abstract
Early and accurate diagnosis of HIV is key for the reduction of transmission and initiation of 
patient care. The availability of a rapid nucleic acid test (NAT) for use at the point-of-care (POC) 
will fill a gap in HIV diagnostics, improving the diagnosis of acute infection and HIV in infants 
born to infected mothers. In this study, we evaluated the performance of non-instrumented nucleic 
acid amplification, single-use disposable (NINA-SUD) devices for the detection of HIV-1 in whole 
blood using reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) with 
lyophilized reagents. The NINA-SUD heating device harnesses the heat from an exothermic 
chemical reaction initiated by the addition of saline to magnesium iron powder. Reproducibility 
was demonstrated between NINA-SUD units and comparable, if not superior, performance for 
detecting clinical specimens was observed as compared to the thermal cycler. The stability of the 
lyophilized HIV-1 RT-LAMP reagents was also demonstrated following storage at −20, 4, 25, and 
30°C for up to one month. The single-use, disposable NAT minimizes hands-on time and has the 
potential to facilitate HIV-1 testing in resource-limited settings or at the POC.
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1. Introduction
HIV diagnostic tests continue to evolve as technology moves towards earlier detection of 
HIV post-infection. Early detection facilitates early initiation of antiretroviral therapy 
(ART), which in turn reduces the risk of disease progression, lowers the likelihood of 
transmission, and improves the overall quality of life for the infected individual (NIH, 2015). 
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To date, the earliest detectable marker for HIV infection is viral RNA, which can be detected 
in plasma as early as 7 days post infection (Keele et al., 2008; Lee et al., 2009). One of the 
biggest gaps in the field of HIV diagnostics is the lack of availability of nucleic acid test 
(NAT) platforms for point-of-care (POC) use. In the US, there remains only one FDA-
approved NAT for diagnosis of HIV-1, the APTIMA HIV-1 RNA Qualitative Assay (Hologic 
Inc., Marlborough, MA). The APTIMA is strictly a laboratory platform, which can limit 
access to nucleic acid testing and increase time to result, in cases that require a supplemental 
NAT result. Dried blood spots have improved accessibility to NAT testing, since samples can 
be collected at field sites and shipped at room temperature to a central laboratory, however, 
turnaround time is high and loss to care is a likely outcome (Johannessen, Troseid, and 
Calmy, 2009). Recently, HIV test development has shifted towards simplified, integrated, 
portable NAT platforms that may extend the utility of nucleic acid-based tests for POC use. 
Several rapid NAT platforms are in development or the early stages of commercialization, 
including: Cobas Liat System (Roche Molecular Systems, Branchburg, NJ), Alere q HIV-1/2 
Detect (Alere Inc., Jena, Germany), SAMBA (Diagnostics for the Real World, Ltd., 
Sunnyvale, CA), and GeneXpert systems (Cepheid, Sunnyvale, CA) (Lee et al., 2010; 
Tanriverdi, Chen, and Chen, 2010). These platforms are similar in design and consist of pre-
loaded test cartridges or tubes and a benchtop analyzer. None of these moderate complexity 
platforms are currently available for purchase in the US.
In the US or similar developed countries, POC may refer to testing clinics, community 
outreach centers, prisons, mobile testing units, and other testing sites, where laboratory test 
operation is not feasible. HIV diagnosis at the POC in resource limited settings offers 
additional challenges. Such areas are often where HIV prevalence is high and targeting HIV 
screening and early diagnosis and treatment is especially critical. In addition to cost and 
training considerations, key limiting factors in these areas may also include availability of 
clean water, refrigeration, and reliable electricity sources (Lee et al., 2010). Rapid HIV 
antibody-based tests have made HIV diagnosis possible in these settings, as most rapid tests 
are self-contained, relatively stable, and disposable. The development of a rapid NAT adds 
an additional level of complexity since the amplification step requires a constant heat source 
and temperature cycling, in the case of polymerase chain reaction (PCR)/reverse 
transcription PCR (RT-PCR), and cold chain storage is needed for the amplification 
reagents. To simplify the overall design of the NAT platform and reduce material costs, 
alternative sources of heat, coupled to isothermal amplification methods, have been explored 
for rapid NAT development. One such approach involves harnessing the heat from 
exothermic chemical reactions (LaBarre et al., 2011; Labarre et al., 2010). Prototype 
electricity-free, non-instrumented nucleic acid (NINA) heaters have been developed and 
demonstrated for detection of malaria and HIV (Labarre et al., 2010; Lillis et al., 2014; 
Sema et al., 2015; Singleton et al., 2014). NINA heaters consist of an insulated, reusable 
unit, which houses the chemical reactants (e.g. CaO or Mg-Fe) that provide the heat source 
for amplification. Depending on the optimal temperature for the specific isothermal 
amplification method, the design of the NINA unit is flexible and has been constructed from 
an insulated thermos or small soufflé cup (Curtis et al., 2012; LaBarre et al., 2011).
Loop-Mediated Isothermal Amplification (LAMP) exhibits several attractive characteristics 
for the integration into a rapid NAT platform. LAMP or RT-LAMP (reverse transcription-
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LAMP) assays have been developed for the detection of a wide range of bacterial and viral 
targets, including HIV (Curtis, Rudolph, and Owen, 2008; Curtis, Rudolph, and Owen, 
2009). LAMP is a single-step amplification reaction that requires six primers specific for 
eight separate sequences within the target region, contributing to the high specificity 
associated with the amplification method (Nagamine, Hase, and Notomi, 2002; Notomi et 
al., 2000). A large amount of amplicon is generated from the amplification reaction within 
60 minutes or less (Mori, Hirano, and Notomi, 2006). Capitalizing on the abundant amplicon 
or magnesium pyrophosphate byproduct, several groups have developed LAMP detection 
methods that enable immediate visual detection of the amplified products. In addition to 
non-specific detection methods, such as measuring turbidity, use of intercalating or metal 
indicator fluorescent dyes, and colorimetric detection (Curtis et al., 2008; Goto et al., 2009; 
Mori et al., 2001; Tanner, Zhang, and Evans, 2015), sequence-specific detection methods 
have been developed, using fluorescent-labeled primers or probes (Curtis et al., 2009; Mori 
et al., 2006). LAMP/RT-LAMP is less sensitive to biological inhibitors as compared to 
traditional amplification methods and direct amplification from clinical specimens, such as 
plasma, whole blood, and oral fluid, has been demonstrated for HIV-1 (Curtis et al., 2008; 
Curtis et al., 2009; Liu et al., 2011).
We previously demonstrated the performance and stability of NINA heaters for amplification 
of HIV-1 in whole blood by RT-LAMP (Curtis et al., 2012). In moving towards a single-use, 
disposable NAT, significant design modifications have been made to the NINA platform in 
order to miniaturize the unit, minimize hands-on time, and eliminate the need for cold chain 
storage. The NINA-SUD (single-use disposable) heaters contain the integrated reactants and 
are equipped with temperature indicating labels, which alert the test user when the device 
has reached temperature. In this study, we evaluated the performance of the NINA-SUD 
heaters for amplification of HIV-1 using lyophilized RT-LAMP reagents, which contain a 
fluorescent probe/quencher pair for immediate visual detection of amplified products. The 
stability of the lyophilized RT-LAMP reagents was also evaluated following storage at 
varying temperatures to determine the feasibility of eliminating reagent cold chain storage.
2. Material and Methods
2.1. Linearity Panels
HIV-1 DNA and RNA linearity panels were generated from OM-10.1 cells and supernatant 
from 8E5 cells, respectively, as described in detail (Rudolph et al., 2015). The 104 DNA 
copies/mL and 105 RNA copies/mL panel members were used as DNA and RNA standards, 
respectively, for the lyophilized reagent stability evaluation. HIV-2 NIH-Z purified virus 
(Advanced Biotechnologies Inc., Columbia, MD) was included to generate a negative 
control. DNA was extracted from the OM-10.1 cells using a QIAamp DNA Blood Mini kit 
(Qiagen, Valencia, CA) and RNA was extracted from the 8E5 supernatant and NIH-Z 
purified virus using a QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, CA). Linearity 
panels and negative controls were stored at −80°C until use.
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Whole blood specimens were collected from an IRB-approved study in collaboration with 
the University of Washington (UW). Participants were recruited from the Centers for AIDS 
Research (CFAR) registry (AI027757), which is a database of HIV infected individuals. 
Inclusion criteria for study enrollment were as follows: ≥18 years old, HIV-1 seropositive, 
HIV-1 NAT positive, and no prior history of antiretroviral therapy (ART). Approximately 
10–15 mL of whole blood were collected from a total of 31 HIV-1-infected patients. Blood 
samples were also collected from 50 HIV-1 seronegative patients. Specimens were collected 
at UW and shipped to the Centers for Disease Control and Prevention (CDC) within 24 
hours of collection. HIV-1 viral load testing was performed using the Abbott RealTime 
HIV-1 assay (Abbott Molecular, Abbott Park, Illinois) at the time of sample collection at the 
UW, along with CD4 counts. Upon receipt, whole blood samples were aliquoted in 100–
200μL volumes and stored at −80°C until ready for use.
2.3. RT-LAMP Reagents
A lyophilized preparation of the RT-LAMP amplification reagents, containing HIV-1 reverse 
transcriptase (RT) primers, was freeze-dried at PATH using a Millrock LD85 Lyophilizer 
(Millrock Technology, Inc., Kingston, NY). The RT primer sequences, along with a 
quencher probe, have been described elsewhere (Curtis et al., 2012; Rudolph et al., 2015). 
The reaction mix contained the following components: 0.2 μM each of F3 and B3 primers, 
1.6 μM each of FIP and BIP primers, 0.8 μM each of LoopF and LoopB primers (LoopF 
contains a 5′ HEX label), 0.8 μM of the Black Hole Quencher 1 (BHQ1)-labeled quencher 
probe, 8 mM MgSO4, 1.4 mM dNTPs (Sigma-Aldrich, St. Louis, MO), 1X Isothermal 
Amplification Buffer (New England Biolabs, Ipswich, MA), 16U glycerol-free Bst 2.0 
WarmStart DNA Polymerase (New England Biolabs, Ipswich, MA), 2U AMV Reverse 
Transcriptase (Life Technologies, Carlsbad, CA), and 5% trehalose (Life Sciences Advanced 
Technologies, St. Petersburg, FL). The reagents were lyophilized directly in 200μL PCR 
tubes (Agilent Technologies, Santa Clara, CA) and capped immediately after removing from 
the lyophilizer. The tubes were sealed in Vapor-Loc foil pouches (TigerPak Inc., Moonachie, 
NJ) with desiccant packs (Desiccare, Inc., Reno, Nevada) and stored at −20°C until ready for 
use.
2.4. Non-instrumented nucleic acid (NINA) heaters
Expanding upon the utility of the previously demonstrated NINA reusable heating devices, 
PATH (Seattle, WA) has developed a miniaturized, single-use disposable (NINA-SUD) 
heater prototype (Curtis et al., 2012; Sema et al., 2015; Singleton et al., 2014) (Figure 1). 
Mg-Fe fuel powder (Luxfer Magtech Inc., Cincinnati, OH), contained in a round pouch 
made from heat-sealable, hydrophilic teabag filter paper (Muslin Bag, San Diego, CA) was 
added to the base of each heater. To initiate the exothermic reaction, saline (2.0% NaCl in 
distilled water; Sigma-Aldrich, St. Louis, MO) is added to an external reservoir and 
delivered to the Mg-Fe fuel pouch via capillary transport in a porous, glass fiber paper media 
(Ahlstrom Corporation, Helsinki, Finland). The fuel pouch wicks the solution into the 
device, activating the exothermic reaction and subsequent temperature-buffered heat output 
to the PCR tubes. Steam generated by the exothermic reaction is channeled into a chamber 
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containing cotton balls (Amazon.com, Seattle, WA) to prevent visible steam from escaping 
the device. Steam passing into the condensing chamber triggers the irreversible color-
changing temperature indicating labels (49°C Labels, Tempil, Elk Grove Village, IL). The 
labels indicate whether the exothermic chemical reaction has initiated, which is not an 
indication of the temperature of the samples. To reduce heat loss and maximize temperature 
holdover time, the devices were insulated with low density polyvinyl chloride (PVC) foam 
(Mcmaster-Carr, Elmhurst, IL), milled to shape with a CNC 3-axis mill (Haas Automation 
Inc, Oxnard, CA), and fastened with double-sided acrylic tape adhesive (MBK Tape 
Solutions, Chatsworth, CA). The exothermic Mg-Fe oxidation reaction is thermally coupled 
with palmitic acid, which acts as a phase change material (PCM) on the temperature interval 
58–61°C. To increase thermal conductivity of the composite and reduce the warm-up time of 
the system, graphene nanoparticles (Angstron Materials, Dayton, OH) were mixed (20% 
mass fraction) with the palmitic acid (Sigma-Aldrich, St. Louis, MO). The structural plastic 
components were rapid-prototyped using UV-cure photopolymer 3D printing (Objet, 
Rehovot, Israel). The NINA-SUD devices were designed with three sample ports to hold 
three 100μL PCR tubes (ThermoFisher Scientific, Waltham, MA), which allows for 
inclusion of a test specimen, positive control, and negative control. The NINA-SUD heaters 
were manufactured at PATH and shipped to the CDC for testing.
To ensure quality control in the manufacturing process, one device from each production lot 
(n=10) was tested for compliance to performance specifications (Figure 2). Additionally, 
PATH archived one device from each production lot as a representative for future 
performance analysis, if needed.
2.5. NINA-SUD Operation
Prior to initiating the RT-LAMP reaction, the PCR tubes strips were removed from the foil 
pouches and the lyophilized reagent pellets were reconstituted with 15μL of RNase-free 
water containing 1.33M Betaine (Sigma-Aldrich). The reconstituted reagents were 
transferred to 100μL PCR tubes and 10μL of sample was added to the tube. To prevent 
evaporation of the reactants, 15μL mineral oil (Hologic, Inc., San Diego, CA) was overlaid 
on top of the reaction mix in each tube. The PCR tubes were added to the sample ports in the 
heater and the foam insulation lid was placed on top to close the sample compartment. To 
initiate the exothermic reaction, 6mL of 2.0% NaCl solution was dispensed into the reservoir 
on the outside of the NINA-SUD. Initiation of the exothermic chemical reaction within the 
NINA-SUD devices was measured indirectly by visually monitoring the color change of the 
temperature indicating labels.
To evaluate the performance of the NINA-SUD heaters, 15 HIV-1-positive specimens, 
stratified by viral load, and 5 HIV negative samples were tested. The total sample number 
was determined based on the availability of test materials and number of specimens with 
detectable viral loads. Each sample was tested in triplicate (1 replicate per device) to 
evaluate the consistency of the heaters. For comparison, the samples were also tested in 
triplicate in a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA). For the 
baseline thermal cycler reaction, the reaction mix was prepared fresh as described (Rudolph 
et al., 2015). Amplification was confirmed by determining fluorescence of the reaction tubes 
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on the UV transilluminator of a ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, 
CA).
2.6. Reagent stability evaluation
The lyophilized amplification reagents were prepared as described for the NINA-SUD heater 
evaluation, with the exception that the quencher probe was not included in the reagent mix. 
The quencher was omitted to prevent inhibition during the real-time reaction. One 8-tube 
strip was packaged per foil pouch. Upon receipt, the foil pouches containing the reagents 
strips were stored at −20°C, 4°C, 25°C (room temperature), or 30°C. The tubes were 
removed from storage conditions and tested on days 0, 7, 14, 21, and 28 using DNA and 
RNA standards. The DNA standard containing 104 DNA copies/mL and RNA standard 
containing 105 RNA copies/mL were tested in triplicate using a Stratagene Mx3005P real-
time platform (Agilent Technologies, Santa Clara, CA). The amplification was set for 60 
minutes at 60°C. The time to positive result was determined by Ct values for all standards. 
Each cycle corresponded to one minute of amplification time.
3. Results
3.1. Performance of NINA-SUD devices
The average temperature recording for 10 representative NINA-SUD devices (one from each 
production lot) is shown in Figure 2. The heating devices reached 60°C within an average of 
11 minutes from the time that the reactants were initiated. The devices maintained a 
temperature of at least 60°C for an average of 35.8 minutes before a decline of ≥1 degree 
was noted.
Overall, the NINA-SUD devices exhibited comparable performance, if not superior, to the 
thermal cycler in detecting HIV in whole blood from HIV-1 infected individuals (Table 1). 
The reproducibility of the NINA-SUD devices, as measured by triplicate testing of each 
sample, was slightly greater as compared to the replicates tested in the thermal cycler (Table 
1). In the NINA-SUD devices, all samples with a viral load (VL) ≥104 copies/mL were 
detected in all three replicates. Of the six samples with a VL <104 copies/mL, four were 
detected in all three or 2/3 replicates. The remaining two samples with a VL < 2000 
copies/mL were not detected at all in the NINA-SUD devices or thermal cycler. Sample 
UW10 (VL=3115 copies/mL) was detected in all three replicates in the NINA-SUD devices 
but not detected at all in the thermal cycler. No amplification was observed with the HIV-1 
negative samples in either the NINA-SUD devices or thermal cycler.
3.2. Stability of Lyophilized HIV-1 RT-LAMP Reagents
For the stability evaluation of the lyophilized RT-LAMP reagents, the average time to 
positivity for the amplification reaction is plotted for DNA and RNA standards relative to 
storage time and temperature (Figure 3). The standard for comparison at −20°C storage 
temperature was 10.7 minutes for DNA and 12.7 minutes for RNA at T=0. For the standard 
storage conditions, the amplification time remained stable for all time points, as indicated by 
a time to positivity of 11 minutes for DNA and 11.3 minutes for RNA after 27 days. At 
elevated temperatures, relative to −20°C, the amplification time was slightly increased at 25 
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and 30°C by day 27. The time to positivity at day 27 was 11, 12.3, and 13.3 minutes for the 
storage temperatures 4, 25, and 30°C, respectively. Similarly, a small increase in the 
amplification time was noted for RNA when the lyophilized reagents were stored at 25 and 
30°C. At day 27, the time to positivity was 12, 13.3, and 13.7 minutes for the storage 
temperatures 4, 25, and 30°C, respectively.
4. Discussion
Rapid tests have transformed the field of HIV diagnostics, facilitating HIV screening at the 
POC, where resources are often limited. Rapid POC HIV testing considerably reduces 
turnaround time, providing immediate knowledge of a preliminary positive test result and 
improved linkage to care. HIV antibodies become detectable by most antibody-based assays 
within 3–6 weeks post-infection (Branson, 2007; Butto et al., 2010). In acute or early 
infection, antibody tests may yield false-negative test results if an individual is tested prior to 
or during early seroconversion. The availability of a cost-effective, rapid NAT could 
potentially improve detection of acute infection at the POC and reduce the need for follow-
up laboratory testing when supplemental NAT testing is required. The primary goal of the 
current study was to demonstrate the performance of a prototype single-use, electricity-free 
heating device for the detection of HIV-1 by RT-LAMP. Previously, it has been demonstrated 
that the HIV-1 RT-LAMP assay can reduce the window of detection between infection and 
seroconversion (Rudolph et al., 2015). The results from this study demonstrate a step 
forward towards the development of a single-use, rapid NAT that may supplement rapid 
antibody testing at the POC.
The simplified NINA-SUD device is made from low-cost, fully incinerable materials, 
estimated to cost less than $1.00 USD to manufacture at scale in the current embodiment. 
Since electricity or batteries are not required and the NINA-SUD materials are non-toxic, 
disposal of the device and its components poses no hazardous risk. The temperature 
indicator labels and integrated chemical reactants are inexpensive yet valuable modifications 
to the device design, further reducing hands-on time. The device operation requires minimal 
training and alerts the test user when the heating device has reached the indicated 
temperature, ensuring the validity of the run. This study, along with previous NINA 
prototype evaluations, demonstrates the flexibility of the housing materials for the 
exothermic chemical heating device, especially when coupled to isothermal amplification 
methods (Curtis et al., 2012; Lillis et al., 2014; Sema et al., 2015). Future modifications to 
the NINA-SUD design intend to reduce the size of the unit, eliminate the need for PCR 
tubes, and integrate the ambient temperature-stable, lyophilized amplification reagents. An 
additional important modification to the RT-LAMP assay was the use of an ambient 
temperature-stable lyophilized reaction mix, containing a fluorescent-labeled primer and 
quencher pair, which eliminates the need to open the tube after the amplification reaction is 
complete and reduces the risk of amplicon contamination. For convenience, a 
transilluminator was used to visualize the reaction tubes in this study, however, a handheld 
UV light or portable, battery-operated fluorescent reader can be used at field sites.
Despite the reduction in size and complexity of the NINA-SUD devices, the design 
modifications were not at the detriment of the assay performance. The reproducibility 
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between devices and overall performance for amplifying clinical specimens was similar to 
the reusable, thermos-style prototype (Curtis et al., 2012). Although the temperature of the 
NINA-SUD devices began to decline from the optimal 60°C reaction temperature prior to 
the completion of the 60 minute amplification step, initial validation studies indicated that 
the majority of all amplification reactions occur within 30 minutes (data not shown). 
Importantly, all clinical specimens were detected within the reported limit of detection of the 
assay for RNA, which is 104 copies/mL (Rudolph et al., 2015). Since the RT-LAMP reaction 
can amplify from RNA, as well as DNA targets, the contribution from proviral DNA cannot 
be excluded and may explain amplification of specimens with a VL <104 RNA copies/mL. 
In this study, the NINA-SUD devices appeared to perform slightly better as compared to a 
thermal cycler. A direct comparison between the lyophilized RT-LAMP reagents and freshly 
prepared reagent mix showed comparable results (data not shown); therefore, it is not 
expected that the performance discrepancy was related to the amplification reagents. One 
plausible explanation for these findings is the slight temperature deviations or fluctuations in 
the heaters may be favorable for the RT-LAMP reaction, especially if slightly higher or 
lower reaction temperatures are more favorable for certain patient sequences.
In this study, we demonstrated the stability of the lyophilized HIV-1 RT-LAMP reagents and 
fluorescent label when stored at room and elevated temperatures, which validates the 
feasibility for POC use, where refrigeration might not be available. With the final version of 
the rapid NAT, extensive stability studies will be needed to fully characterize the shelf-life 
and storage conditions of the reaction materials. The next steps towards development of the 
NINA-SUD are designed toward the incorporation of a whole blood sample preparation step 
into the device and inclusion of RT-LAMP primers capable of amplifying group M HIV-1 
sequences. In the current study, subtype B reverse transcriptase-specific primers were used 
for convenience as the focus of our laboratory is HIV diagnostics in the US and; therefore, 
US-derived standards are readily available. Conserved RT-LAMP primers, targeting a region 
within the HIV-1 integrase gene, have also been developed for detection of subtype B 
infections (Rudolph et al., 2015). Validation of the HIV-1 INT RT-LAMP primers, optimized 
for detection of group M, is currently underway.
A limitation of the NINA-SUD evaluation was the relatively small number of clinical 
specimens from HIV-1 infected individuals. The goal of this IRB-approved study was to 
obtain whole blood from recently diagnosed HIV-1 infected participants, however, low 
enrollment expectations dictated a broader recruiting mechanism, which included primarily 
chronic cases of HIV infection. Given that most previously diagnosed, HIV-infected 
individuals in the US are receiving antiretrovirals, it is challenging to obtain whole blood 
samples from a large number of study participants who are not virally suppressed. The 
projected enrollment of HIV positive study participants was at least 50, however, only 31 
participants enrolled during the study period. Of the 31 study subjects, approximately 1/3 
exhibited undetectable plasma viral loads or levels under 1000 RNA copies/mL and an 
additional seven subjects had viral loads under 104 RNA copies/mL. Future validation 
studies may require a revised recruiting mechanism or expansion to study sites outside of the 
US.
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The NINA-SUD device in conjunction with the HIV-1 RT-LAMP assay is a promising rapid, 
cost-effective NAT platform that requires minimal training and hands-on time. The single-
use device has the potential to supplement rapid serologic testing at the POC and increase 
the number of individuals that are aware of their HIV status.
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• A rapid, single-use nucleic acid amplification device (NINA-SUD) was 
evaluated.
• An exothermic chemical reaction provides the heat source for the 
NINA-SUD devices.
• We demonstrated amplification from whole blood by HIV-1 RT-LAMP 
in the NINA-SUD.
• Reproducibility was observed between NINA-SUD units and a thermal 
cycler.
• Stability of the lyophilized HIV-1 RT-LAMP reagents was 
demonstrated.
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Figure 1. NINA-SUD device
(A) A cross-sectional diagram of the NINA-SUD device. Removable foam insulation lid (a) 
allows insertion of 3– 100uL PCR tubes (b) into the device. An exothermic chemical 
reaction fuel pouch (d) delivers heat to palmitic acid PCM (c), buffering temperature to 
amplification specification. The reaction by-product steam is channeled into a condensing 
chamber (f). The PCR tube holder and support structure is made from rapid-prototyped 
plastic (e). (B) A photograph of the NINA-SUD device before and after initiation of the 
exothermic chemical reaction, along with the PCR tubes post-reaction. From left to right, the 
PCR tubes contain a sample, positive control, and negative control.
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Figure 2. NINA-SUD temperature profile
The average temperature of 10 NINA-SUD test devices (black line), recorded for 60 minutes 
post-initiation of chemical reactants. The shaded gray area of the plot represents the standard 
deviation.
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Figure 3. Lyophilized RT-LAMP reagent stability
The total amplification time until positivity is plotted for DNA (A) and RNA (B) over days 
the lyophilized reagents were stored at temperatures of −20°C (solid line, closed circle), 4°C 
(solid line, open circle), 25°C (dashed line, closed circle), and 30°C (dashed line, open 
circle).
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